{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lecouturier J"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["e0265048"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8979436"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(4)"],"pubmed_abstract":["<h4>Objectives</h4>Cutaneous melanoma rates are steadily increasing. Up to 20% of patients diagnosed with AJCC Stage I/II melanomas will develop metastatic disease. To date there are no consistently reliable means to accurately identify truly high versus low-risk patient subpopulations. There is hence an urgent need for more accurate prediction of prognosis to determine appropriate clinical management. Validation of a novel prognostic test based on the immunohistochemical expression of two protein biomarkers in the epidermal microenvironment of primary melanomas was undertaken; loss of these biomarkers had previously been shown to be associated with a higher risk of recurrence or metastasis. A parallel qualitative study exploring secondary care health professional and patient views of the "],"journal":["PloS one"],"pubmed_title":["Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study."],"pmcid":["PMC8979436"],"funding_grant_id":["II-LA-0417-20001"],"pubmed_authors":["Lecouturier J","Labus M","Ellis RA","Lovat PE","Bosomworth H"],"additional_accession":[]},"is_claimable":false,"name":"Health professional and patient views of a novel prognostic test for melanoma: A theoretically informed qualitative study.","description":"<h4>Objectives</h4>Cutaneous melanoma rates are steadily increasing. Up to 20% of patients diagnosed with AJCC Stage I/II melanomas will develop metastatic disease. To date there are no consistently reliable means to accurately identify truly high versus low-risk patient subpopulations. There is hence an urgent need for more accurate prediction of prognosis to determine appropriate clinical management. Validation of a novel prognostic test based on the immunohistochemical expression of two protein biomarkers in the epidermal microenvironment of primary melanomas was undertaken; loss of these biomarkers had previously been shown to be associated with a higher risk of recurrence or metastasis. A parallel qualitative study exploring secondary care health professional and patient views of the ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-05T15:52:55.27Z","creation":"2025-04-05T15:52:55.27Z"},"accession":"S-EPMC8979436","cross_references":{"pubmed":["35377887"],"doi":["10.1371/journal.pone.0265048"]}}